Ignite Creation Date:
2025-12-25 @ 2:35 AM
Ignite Modification Date:
2026-06-27 @ 9:54 PM
Study NCT ID:
NCT01336634
Status:
COMPLETED
Last Update Posted:
2022-04-04
First Post:
2011-04-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
113928
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None